Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ansun Biopharma Reports China Approvals for Two Trials of Anti-Infective

publication date: Oct 29, 2019

Ansun Biopharma, a San Diego anti-infectives company, announced two clinical trial approvals in China for its novel anti-infective, DAS181: a China extension of Ansun's global Phase III DAS181 trial for hospitalized, immunocompromised patients with lower respiratory tract parainfluenza virus infection, and a Phase IIb trial to treat severe hospitalized influenza infection. In the last 18 months, Ansun has raised $165 million to support parallel development of these two trials around the globe. The company noted there are no approved drugs to treat either condition in patients who do not respond to the standard of care. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital